Callisto currently has 3 trials ongoing for Atiprimod:
1. Callisto protocol CP-106. A Phase II Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients with Low to Intermediate Grade Neuroendocrine Carcinoma. This is a Phase I/IIa clinical trial to identify the maximum tolerated dose of atiprimod and to evaluate the safety of atripimod in patients with refractory or relapsed multiple myeloma.
For further information, please go to www.clinicaltrials.gov/
ClinicalTrials.gov Identifier: NCT00388063
How to enroll: This trial has completed enrollment.
2. Callisto protocol CP-AT202-07. A Phase II Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients with Low to Intermediate Grade Neuroendocrine Carcinoma. This study is an extension trial for Callisto protocol CP-106.
For further information, please go to www.clinicaltrials.gov/
ClinicalTrials.gov Identifier: NCT00430014
How to enroll: This trial is only available to patients who have completed CP-106.
3. Callisto protocol CP-101. An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients with Refractory or Relapsed Multiple Myeloma. This is a Phase I/II multi-center, open label, dose escalation study to identify the maximum tolerated dose (MTD) of liposomal annamycin and to evaluate the safety of liposomal annamycin in patients with refractory or relapsed acute lymphocytic leukemia.
For further information, please go to www.clinicaltrials.gov/
ClinicalTrials.gov Identifier: NCT00086216
How to enroll: This trial has completed enrollment.